CN Patent
CN109069481A — 用于恢复突变p53功能的方法和化合物
Assigned to PMV Pharmaceuticals Inc · Expires 2018-12-21 · 7y expired
What this patent protects
癌基因和肿瘤抑制基因的突变促进癌症的发展和进展。本公开描述了用于恢复p53突变体的野生型功能的化合物和方法。本发明的化合物可与突变p53结合并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应物的能力。所公开的化合物可用来减低含有p53突变的癌症的进展。
USPTO Abstract
癌基因和肿瘤抑制基因的突变促进癌症的发展和进展。本公开描述了用于恢复p53突变体的野生型功能的化合物和方法。本发明的化合物可与突变p53结合并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应物的能力。所公开的化合物可用来减低含有p53突变的癌症的进展。
Drugs covered by this patent
- Zepatier (ELBASVIR) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.